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The B cell repertoire is diversified during im-
mune responses through somatic hypermutation 
(SHM) and class switch recombination (CSR) to 
generate highly specific and adapted humoral re-
sponses. SHM introduces point mutations in the 
variable region of Ig genes, thereby increasing   
antibody affinity for antigen (1). CSR modulates 
antibody effector functions by replacing the anti-
body isotype expressed (from IgM to IgG, IgE, or 
IgA), while retaining the antigen-binding speci-
ficity of the receptor (2). SHM and CSR require 
the expression of activation-induced cytidine de-
aminase (AID) (3, 4), an enzyme that deaminates 
cytidines in DNA and that generates U:G mis-
matches in Ig genes (5, 6). Lesions induced by 
AID are processed by base excision repair and/or 
mismatch repair enzymes (including uracyl DNA 
glycosylase [UNG], APE1, APE2, MSH2, and 
MSH6) to generate mutations or double-stranded 
DNA breaks (DSBs) in Ig genes (1, 2). CSR is a 
region-specific recombination reaction that in-
volves the joining of repetitive, but nonhomolo-
gous, switch region DNA sequences that can be 
separated by up to 200 kb and that requires DSBs 
as intermediates (2, 7). These DNA breaks acti-
vate DNA damage response proteins, including 
the PI3-like protein kinase ataxia-telangiectasia 
mutated (ATM), the histone variant H2AX, the 
MRN complex (Nbs1, Mre11, and Rad50), 
MDC1, and 53BP1 to promote appropriate re-
pair and efficient long-range recombination (7). 
Consistent with this, deficiency in any of these 
genes results in defective CSR (2, 7). The joining 
step of the reaction was believed to be primarily 
mediated by the nonhomologous end-joining 
pathway (NHEJ) (2, 7). However, recent evi-
dence indicates that an alternative pathway that is 
independent of XRCC4 and DNA ligase IV, and 
which is biased toward microhomology usage, 
has a significant contribution in the resolution of 
AID-induced DNA breaks during CSR (8–10).
Despite the numerous pathways and proteins 
involved in sensing and mediating the repair of 
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Immunoglobulin class switch recombination (CSR) is initiated by DNA breaks triggered by 
activation-induced cytidine deaminase (AID). These breaks activate DNA damage response 
proteins to promote appropriate repair and long-range recombination. Aberrant processing 
of these breaks, however, results in decreased CSR and/or increased frequency of illegiti-
mate recombination between the immunoglobulin heavy chain locus and oncogenes like  
c-myc. Here, we have examined the contribution of the DNA damage sensors Parp1 and 
Parp2 in the resolution of AID-induced DNA breaks during CSR. We find that although Parp 
enzymatic activity is induced in an AID-dependent manner during CSR, neither Parp1 nor 
Parp2 are required for CSR. We find however, that Parp1 favors repair of switch regions 
through a microhomology-mediated pathway and that Parp2 actively suppresses IgH/c-myc 
translocations. Thus, we define Parp1 as facilitating alternative end-joining and Parp2 as a 
novel translocation suppressor during CSR.
© 2009 Robert et al.  This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.jem.org/misc/terms.shtml). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
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vation in mice leads to increased sensitivity to ionizing radiation 
and alkylating agents and to genomic instability (24, 26). Fur-
thermore, genetic interactions between Parp1, Parp2, and ATM 
have been described and ATM/Parp1/, ATM/Parp2/, 
and Parp1/Parp2/ mice display embryonic lethality (26–28). 
Here, we have examined the role of Parp1 and Parp2 in re-
sponding  to  AID-induced  DNA  breaks  generated  during 
CSR. We show that Parp1 and Parp2 have nonredundant roles   
and that Parp1 facilitates repair through the alternative NHEJ, 
whereas Parp2 actively suppresses the generation of IgH/c-myc 
translocations induced by AID during Ig CSR.
RESULTS
AID-dependent Parp activity is induced in B cells 
undergoing CSR
Induction of DNA damage results in the activation of Parp1 
and Parp2, which are enzymes that catalyze the poly(ADP) 
ribosylation of multiple target proteins to promote DNA re-
pair (23). This activity can be readily visualized by Western 
blotting using an antibody specific for the polymer of ADP-
ribose (PAR). As one of the main targets of Parp activity is 
Parp1 itself, the antibody primarily reveals the automodified 
form of Parp1 and a smear above corresponding to Parp1 con-
taining  polymers  of  different  length  (29).  To  determine 
whether Parp activity is induced during CSR we stimulated 
CH12 cells with TGF-, Il-4 and anti-CD40 antibody. Un-
der these conditions, the IgM+ CH12 lymphoma cell line 
undergoes very efficient CSR to IgA (30). After 72 h in culture 
we assayed for Parp activity by Western blotting (Fig. 1 A). We 
found that Parp activity is induced in CH12 cells at levels 
comparable to those observed in cells that were exposed to 
H2O2 (Fig. 1 A), treatment known to induce a strong Parp 
activity (31). To determine whether Parp activity is also in-
duced in primary splenic B cells, we cultured purified resting 
B cells from wild-type mice in the presence of LPS and IL-4 
DNA damage, AID-induced DNA breaks can be aberrantly 
resolved in cis to produce internal deletions within the Ig heavy 
chain (IgH) locus (11–14), and in trans to produce chromo-
somal translocations (15–19) that have the potential to promote 
cellular transformation (20). Indeed, translocations involving 
the IgH locus are frequently found in almost all cancer-associ-
ated chromosomal translocations in mature B cell lymphomas 
and in multiple myeloma (21). Strong evidence supporting the 
hypothesis that reciprocal translocations involving the IgH and 
oncogenes like c-myc are byproducts of the SHM and CSR 
reactions has been recently provided (15–19). The generation 
of IgH/c-myc translocations is dependent on AID expression, 
AID’s catalytic activity, on the processing of AID-induced U:G 
mismatches in DNA by UNG, and on the transcriptional status 
of the c-myc locus (15–19). In addition, suppression of IgH/ 
c-myc translocations requires the establishment of p53-mediated 
checkpoints through the activation of Nbs1, ATM, and/or the 
tumor suppressor p19Arf (17). Furthermore, DSB resolution 
into chromosomal translocations seems to be independent of 
the NHEJ components Ku80, XRCC4, and DNA ligase IV, 
indicating that an alternative NHEJ is involved in mediating 
aberrant interchromosomal joining (9, 17).
Poly(ADP)-ribose polymerases catalyze the covalent attach-
ment of poly(ADP)-ribose units on amino acid residues of ac-
ceptor proteins using -NAD+ as a substrate (22). The resulting 
poly(ADP)ribosylation is an immediate and transient posttrans-
lational modification of target proteins that has been involved 
in modulating many essential cellular processes, including tran-
scription, replication, and DNA repair (22). Among the 17 
members of the Parp family of proteins described to date, the 
best studied and characterized are the founding member Parp1 
and its close homologue Parp2 (23). These two enzymes are 
unique in that they are the only members of the family that rec-
ognize and are activated by DNA breaks and are believed to be 
DNA damage sensors (23–25). Consistent with this, their inacti-
Figure 1.  AID-dependent Parp activity is induced in B cells undergoing CSR. Western blot analysis of poly(ADP)ribosylation using antibodies spe-
cific for the polymer of ADP-ribose (PAR; top) and -actin (bottom) in whole-cell extracts from CH12 lymphoma and splenic B lymphocytes. (A) CH12 
cells extracts were prepared before or after treatment with PBS or 1 mM H2O2 for 10 min as controls, and before or after stimulation for 3 d with IL-4, 
TGF-, and anti-CD40 antibody. (B) Splenic B cell extracts from wild-type (WT), Parp1/ (24), Parp2/ (26), and AID-deficient (AIDcre/cre; reference 19) B 
lymphocytes were prepared before or after 2–3 d of stimulation with LPS and IL-4 in the presence or absence of 10 and 100 nM KU0058948 Parp inhibi-
tor. Automodified Parp1 is indicated by a vertical line. Numbers below the panel reflect the intensity of bands representing automodified Parp1 relative to 
wild type and after normalization to -actin. Data from two independent experiments are shown (samples were processed at 72 h [experiment 1] and  
48 h [experiment 2]). Molecular weight sizes in kilodaltons (kD) are indicated.JEM VOL. 206, May 11, 2009 
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determined by flow cytometry (Fig. 2). This observation is 
consistent with the finding that Parp inhibition in the I.29 
transformed B cell line also results in enhanced CSR (34).
Parp1 and Parp2 are not required for CSR in splenic B cells
To directly assess the contribution of Parp1 and Parp2 in re-
sponding to AID-mediated DNA breaks during CSR, we tested 
the intrinsic ability of Parp1/ and Parp2/ B lymphocytes to 
undergo CSR in vitro in the presence or absence of KU0058948 
Parp inhibitor (Fig. 3). We purified mature resting B cells from 
the spleen, labeled them with CFSE to track proliferation, and 
stimulated them to undergo CSR to various isotypes by using in 
vitro culture conditions known to induce switching to precise 
isotypes. After 72 h in culture, cells were analyzed by flow cy-
tometry for proliferation (CFSE dye dilution) and Ig surface ex-
pression. We found that deficiency in Parp1 or Parp2 had no 
effect on proliferation in response to LPS, LPS + IL-4, or LPS + 
IFN- stimulation (Fig. 3, A and B, and not depicted). Surpris-
ingly, in contrast to CH12 cells, we found that Parp1/ and 
Parp2/ B cells underwent CSR to IgG1, IgG2b, IgG3, and 
IgG2a at wild-type frequencies (Fig. 3, A–C). Although in our 
hands CSR induction to IgA with LPS + IL-5 + TGF- is not 
very efficient (<2%), we did not observe an increase in CSR in 
Parp1/ or wild-type B cells treated with the Parp inhibitor (not 
depicted). To determine whether Parp2 compensates for Parp1 
deficiency and vice versa, we tested the ability of Parp1/ and 
Parp2/ B cells to undergo CSR in the presence of KU0058948. 
Inhibition of Parp activity in a Parp1-deficient background had 
no effect in either proliferation or in CSR efficiency (Fig. 3,   
A and C). A significant reduction in the frequency of IgG+ cells 
was observed in Parp2/ B cells in the presence of KU0058948 
(Fig. 3, B and C). As CSR is tightly correlated with cell division 
(35), this effect could be explained by reduced proliferation of 
Parp2/ B cells in the presence of the Parp inhibitor (Fig. 3 D). 
Consistent with this, differences in CSR were not significant 
when cells were analyzed for Ig surface expression by gating on 
cell populations having undergone a defined number of cell divi-
sions (Fig. 3 D). Furthermore, we found that AID expression   
(as determined by RT-PCR and Western blot) was unaffected 
by  deficiency  in  Parp1  or  Parp2,  or  by  the  pharmacological   
for up to 72 h. Western blot analysis using the anti-PAR an-
tibody revealed that CSR induction resulted in robust Parp 
activity (Fig. 1 B). This activity was completely abolished by 
the addition of 10 or 100 nM KU0058948, a potent Parp in-
hibitor that has been described to inhibit both Parp1 and 
Parp2 at 100 nM (Fig. 1 B) (32). As expected, the automodi-
fied form of Parp1 was not observed in stimulated Parp1/ 
B cells (Fig. 1 B). In addition, we found that Parp1 automod-
ification was increased on average by twofold (as determined 
by  Western  blot  quantification)  in  Parp2-deficient  B  cells 
(Fig.  1  B).  Thus,  Parp1  activity  is  increased  in  Parp2/  
B cells and most likely Parp1 compensates for the lack of Parp2. 
This finding is consistent with previous reports of increased 
Parp1 activity in Parp2-deficient B cells (33) and with our 
own observations in other Parp2-deficient cell systems (un-
published data). To determine whether the induction of Parp 
activity is dependent on AID expression, we cultured AID-
deficient B cells (obtained from mice bearing a targeted inser-
tion  of  the  CRE  recombinase  cDNA  into  AID’s  exon  1 
[AIDcre/cre]; reference 19) and which display the same pheno-
type as AID/ mice (3) in the presence of LPS and IL-4. We 
found that Parp activity was reduced by 90% in AID-defi-
cient B cells when compared with wild-type B cells (Fig. 1 B). 
The remaining Parp activity may correspond to break-inde-
pendent  Parp  activation,  to  other  modes  of  physiological 
Parp activation, or to activation of other Parp family mem-
bers. We conclude that Parp activity is induced in B cells un-
dergoing CSR, that this activity is increased in Parp2/  
B cells, and that it is dependent on AID expression.
Inhibition of Parp activity results in increased CSR  
in transformed B cell lines
To determine whether pharmacological inhibition of Parp ac-
tivity affects the efficiency of CSR, we stimulated CH12 cells 
in the presence or absence of the Parp inhibitor KU0058948. 
Treatment of CH12 cells with this inhibitor, at concentrations 
that inhibit Parp activity in B cells (Fig. 1) and other systems 
(32), had no effect on cell survival or proliferation (not de-
picted). We found, however, that the addition of KU0058948 
resulted in a two- to threefold increase in CSR efficiency as 
Figure 2.  Pharmacological inhibition of Parp activity results in increased CSR in CH12 cells. CH12 cells were stimulated with IL-4, TGF-, and 
anti-CD40 antibody, in the presence or absence of 10 and 100 nM KU0058948 Parp inhibitor. After 3 d in culture, cells were analyzed by flow cytometry 
for cell surface expression of IgA in three independent experiments. Representative flow cytometry profiles are shown. The percentage of switched cells is 
indicated in each plot.1050 PARP1 AND PARP2 RESPOND TO AID-INDUCED DNA DAMAGE | Robert et al.
and short regions of microhomology at the junction. In the 
absence of the NHEJ proteins XRCC4 or DNA ligase IV, 
switch junctions display a significant increase in microhomol-
ogy and a complete absence of sequences with no micro-
homology  (9).  A  similar  increase  in  homology  was  also 
observed in patients with hypomorphic mutations in DNA 
ligase IV (10). To determine the pathway that catalyzes CSR 
in the absence of Parp1 or Parp2, we cloned and sequenced 
S/S3  switch  junctions  from  LPS-stimulated  wild-type, 
Parp1/,  and  Parp2/  B  cells  (Fig.  4  and  Figs.  S1–S3). 
Comparison of CSR junctions from Parp1-deficient B cells 
to those of controls revealed a significant difference. Wild-type 
inhibition of Parp activity (not depicted). The level of switch 
region sterile transcripts and circle transcripts, generated only 
after successful CSR (36), were detected at similar levels in all 
experimental groups and were not different from those ob-
served in wild-type B cells (not depicted). We conclude that 
Parp1 and Parp2 are not required for CSR in freshly isolated 
splenic B cells.
Reduced microhomology at switch recombination junctions 
in Parp1/ B cells
Switch regions are joined by classical and alternative end-
joining mechanisms and are characterized by small insertions 
Figure 3.  Parp1 and Parp2 are not required for CSR in splenic B cells. Wild-type (WT), Parp1/, and Parp2/ resting splenic B cells were stained 
with CFSE and cultured for 3 d with LPS (CSR to IgG3 and IgG2b); LPS + IL-4 (CSR to IgG1); LPS + IFN- (CSR to IgG2a); and in the presence or absence of 
100 nM KU0058948 Parp inhibitor. Ig surface expression was determined by flow cytometry within the live cell population (gated using ToPro-3 exclusion) 
and using isotype-specific antibodies in at least five independent experiments. Cell division was measured by CFSE dye dilution. (A) IgG1 cell surface ex-
pression of WT and Parp1/ B cells stimulated with LPS + IL-4 in the presence or absence of 100 nM KU0058948. The percentage of switched cells is 
indicated in each plot. (B) IgG1 cell surface expression of WT and Parp2/ B cells stimulated with LPS + IL-4 in the presence or absence of 100 nM 
KU0058948. The percentage of switched cells is indicated in each plot. (C) The mean percentages (± standard deviation) of CSR relative to WT for the 
different isotypes tested are shown (IgG1, light gray bars; IgG3, black bars; IgG2b, white bars; IgG2a, dark gray bars). CSR in WT B cells was set to 100% 
(horizontal line). Statistical significance as determined by an unpaired Student’s t test is indicated as follows: *, P = 0.0073; **, P = 0.0008; ***, P < 0.0001; 
****, P = 0.0004. (D) Flow cytometric analysis of IgG1 expression on CFSE-labeled Parp2/ B cells stimulated with LPS plus IL-4 for 3 d in the presence or 
absence of 100 nM KU0058948 Parp inhibitor. Cell division as measured by CFSE dye dilution is shown at top. The mean percentages (± standard devia-
tion) of cells expressing IgG1 after a specific number of cell divisions is indicated on the bottom.JEM VOL. 206, May 11, 2009 
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are primarily processed through an end-joining mechanism 
not relying on microhomology.
Parp2 suppresses IgH/c-myc translocations during CSR
DNA DSBs induced by AID are believed to be obligatory 
intermediates in CSR. Aberrant processing of these breaks 
results in defective CSR, increased frequency of short-range 
recombination events (11–14), and generation of AID-de-
pendent  chromosomal  translocations  involving  oncogenes 
such as c-myc (15–19). To determine the involvement of 
Parp1  and  Parp2  in  suppressing  IgH/c-myc  translocations 
during CSR, we cultured B cells obtained from wild-type, 
Parp1/, and Parp2/ mice with LPS + IL-4 in the pres-
ence or absence of 100 nM KU0058948 Parp inhibitor. After 
72 h in culture, we determined the frequency of IgH/c-myc 
translocations by long-range PCR (15) and Southern blotting 
(Fig. 5) and analyzed the translocations by sequencing (Figs. 
S4 and S5). Consistent with previous reports (17), we found 
that IgH/c-myc translocations were induced at low frequency 
sequences contained direct joints (21.2%) and small (1–4 nt) 
insertions (5.8%), with most of the remainder sequences 
bearing short homologies (Fig. 4 A). The mean length of 
overlap at the junction was 1.8 bp. Interestingly, Parp1-defi-
cient  sequences  displayed  a  clear  shift  toward  no  micro-
homology (Fig. 4 B), and 57.6% of the sequences had no 
homology and were either direct joints (32.2%) or contained 
small insertions (25.4%). Furthermore, the mean length of 
overlap at the junction was reduced to 1.0 bp (Fig. 4 B; P = 
0.003 vs. wild type). In contrast to Parp1/, no increase in 
the proportion of sequences with no microhomology was 
observed in Parp2/ sequences (Fig. 4 C), which were more 
similar to wild-type in their distribution (Fig. 4 C). The mi-
nor increase in the mean length of overlap at the junction in 
Parp2/ sequences (2.1 bp) was not statistically significant 
when compared with wild type (Fig. 4 C; P = 0.22 vs. wild 
type). We conclude that switch recombination junctions in 
Parp1/ B cells are biased toward no microhomology. Thus, 
in the absence of Parp1, DNA ends generated during CSR 
Figure 4.  Reduced microhomology at switch recombination junctions in Parp1/ B cells. Histograms showing the percentage of S/S3 switch 
junction sequences with indicated nucleotide overlap and obtained from wild-type (A; n = 52), Parp1/ (B; n = 59), and Parp2/ (C; n = 51) LPS-stimu-
lated B cells in at least 5 independent experiments. Mean length of overlap in base pairs (OL) and the number of sequences analyzed (n) is indicated. 
White portion of bars indicates the percentage of sequences with small (1–4 nt) insertions and was as follows: wild type, 5.8%; Parp1/, 25.4%; and 
Parp2/, 3.9%. Switch junction alignments are shown below each panel (additional sequences in Figs. S1–S3). Overlap was determined by identifying the 
longest region at the switch junction of perfect uninterrupted donor/acceptor identity. Sequences with insertions at the junction were scored as having 
no microhomology. S/S3 sequences are shown in the middle. The S and S3 germline sequences (chromosome 12 genomic sequence: NT-114985) are 
shown above and below each junction sequence, respectively. Homology at the junctions is boxed, and the length of overlap is indicated on the right. 
Lowercase letters indicate mutations. Insertions are bolded and underlined. Statistical significance was determined by a Mann-Whitney test: wild-type 
versus Parp1/, P = 0.003; Parp1/ versus Parp2/, P = 0.0006; wild-type versus Parp2/, P = 0.22.1052 PARP1 AND PARP2 RESPOND TO AID-INDUCED DNA DAMAGE | Robert et al.
ity may compensate for the lack of Parp1. To discriminate 
between these two possibilities, we assayed for translocations 
in Parp1/ B cells in the presence of KU0058948 Parp in-
hibitor.  Pharmacological  inhibition  of  Parp  activity  in  a 
Parp1-deficient background resulted in a 3.4-fold increase in 
the translocation frequency (5.2 × 107 translocations/cell; 
Fig. 5 D) when compared with wild-type B cells (P = 0.0318), 
indicating that Parp1 and Parp2 have nonredundant roles and 
that the catalytic activity of Parp2 is required to suppress 
IgH/c-myc translocations during CSR. Consistent with this, 
we found that Parp2 deficiency resulted in a ninefold increase 
in wild-type B cells (1.5 × 107 translocations/cell; Fig. 5 A). 
Interestingly, inhibition of Parp activity in wild-type B cells 
resulted in a 3.8-fold increase in the frequency of IgH/c-myc 
translocations (5.8 × 107 translocations/cell; P = 0.0193; 
Fig. 5 B), suggesting a role for the catalytic activity of Parp1 
and/or Parp2 in suppressing these translocations. In Parp1/ 
B cells, IgH/c-myc translocations accumulated at a frequency 
that was similar to that observed in wild-type B cells (1.5 × 
107 translocations/cell; P = 0.6574; Fig. 5 C), indicating 
that Parp1 does not play an active role in suppressing this type 
of translocation, or alternatively, that Parp2 enzymatic activ-
Figure 5.  Parp2 suppresses IgH/c-myc translocations. Wild-type (WT), Parp1/, Parp2/ B cells, and AIDcre/cre B cells were cultured for 3 d with 
LPS plus IL-4, in the presence or absence of 100 nM KU0058948 Parp inhibitor, and assayed for IgH/c-myc translocations by long-range PCR in three 
to five independent experiments. Representative ethidium bromide stained agarose gels (EtB; left) and corresponding Southern blots using c-myc 
(middle) and IgH (right) probes are shown. The number of translocations found (T) and individual PCR assays done (with template DNA corresponding 
to 105 cells) was as follows: WT, T=3, n = 200; WT + KU0058948, T=12, n = 208; Parp1/, T=3, n = 200; Parp1/ + KU0058948, T=12, n = 232; 
Parp2/, T=40, n = 296; Parp2/ + KU0058948, T=18, n = 319; AIDcre/cre, T=0, n = 188; AIDcre/cre + KU0058948, T=0, n = 188. The corresponding fre-
quency of translocations per cell (T/cell) is indicated underneath each panel and was as follows: WT, 1.5 × 107; WT + KU0058948, 5.8 × 107 (P = 
0.0193 vs. WT); Parp1/, 1.5 × 107 (P = 0.6574 vs. WT); Parp1/ + KU0058948, 5.2 × 107 (P = 0.0318 vs. WT; P = 0.0318 vs. Parp1/); Parp2/, 
13.5 × 107 (P < 0.0001 vs. WT; P < 0.0001 vs. Parp1/; P = 0.0009 vs. Parp1/ + KU0058948); Parp2/ + KU0058948, 5.6 × 107 (P = 0.0139 vs. 
WT; P = 0.5472 vs. WT + KU0058948; P = 0.4837 vs. Parp1/ + KU0058948; P = 0.0006 vs. Parp2/); AIDcre/cre, 0 (P = 0.1360 vs. WT; P = 0.1360 vs. 
Parp1/; P < 0.0001 vs. Parp2/); AIDcre/cre + KU0058948, 0 (P = 0.1360 vs. WT; P = 0.0005 vs. WT + KU0058948; P = 0.0008 vs. Parp1/ + 
KU0058948; P = 0.0003 vs. Parp2/ + KU0058948). Statistical significance was determined using one-tailed exact Fisher’s test. Molecular weight 
sizes in kilobasepairs (kb) are indicated in A and are the same for all panels.JEM VOL. 206, May 11, 2009 
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which was robust and detectable as early as day 2 after stimula-
tion, was not affected by deficiency in either Parp1 or Parp2 or 
by the inhibition of Parp activity. Furthermore, we found no 
differences in the levels of switch region sterile transcripts, and 
circle  transcripts,  which  are  generated  only  after  successful 
CSR. Our results differ from a recent report showing that 
Parp1/ mice display abnormal levels of circulating serum Igs 
(elevated IgG2a and IgA and reduced IgG2b). This study also 
showed that in vitro–stimulated Parp1/ B cells secrete higher 
levels of IgG2a and IgA, but wild-type levels of IgG2b anti-
bodies, despite decreased levels of serum IgG2b (33). Further-
more, Parp1/ B cells secreted wild-type levels of IgG3 and 
IgG2b in response to LPS stimulation, despite undetectable 
levels of AID mRNA at day 3 and a prominent delay in AID 
mRNA accumulation by day 7 (33). A possible explanation for 
the differences observed between both studies may be related 
to the assays used to analyze the CSR reaction. In this work, 
we assessed the intrinsic ability of purified resting B cells to un-
dergo CSR in response to different stimuli in vitro by analyz-
ing the cell surface expression of Igs by flow cytometry and not 
their capacity to secrete antibodies into the culture medium. 
Furthermore, alterations in the level of circulating serum Igs in 
vivo may be influenced by other factors such as the frequency 
of plasma cells, survival of switched B cells, or abnormal B–T 
cell interactions. Indeed, both Parp1/ and Parp2/ mice 
display alterations within the T cell compartment (33, 37).
AID-induced DNA breaks generated during CSR are ulti-
mately joined by pathways that require the Ku70 and Ku80 sub-
units of DNA-PK (14, 38, 39). Given this requirement, it was 
believed that DNA breaks occurring within switch regions dur-
ing CSR were ultimately repaired through NHEJ (2, 7). This 
view however, was recently challenged by experiments showing 
that CSR is only moderately diminished (25–50% reduction) in 
the absence of the NHEJ core components XRCC4 or DNA 
ligase IV (8, 9), indicating that an alternative pathway, indepen-
dent of XRCC4 and DNA ligase IV, can efficiently join AID-
induced DNA breaks (8, 9). Analysis of switch region junctions 
in XRCC4- or DNA ligase IV–deficient B cells revealed that this 
alternative pathway relies on microhomology (9, 10). Further-
more, a substantial fraction of XRCC4-deficient B cells dis-
played chromosomal aberrations, the majority of which involved 
translocations,  supporting  the  hypothesis  that  this  alternative 
end-joining pathway significantly contributes to repairing DNA 
breaks during CSR and that it frequently produces translocations 
in response to AID-induced DNA breaks (9).
DNA breaks generated during CSR are complex and het-
erogeneous in nature, and some DNA ends may be rapidly 
joined through the classical NHEJ, whereas other breaks may 
require extensive end processing, a search for homology, and 
the cleavage of nonhomologous nucleotides before ligation. 
These types of DNA ends may be repaired at a slower rate and 
may be better substrates for the alternative NHEJ (9). Thus, it 
has been proposed that in B cells undergoing CSR, the classi-
cal and alternative NHEJ are in direct competition for DNA 
ends generated in switch region sequences (9). Consistent 
with this, we have found that Parp1 deficiency results in a 
in the translocation frequency (13.5 × 107 translocations/
cell; Fig. 5 E) when compared with wild-type B cells (P < 
0.0001). Thus, Parp2 is required to suppress IgH/c-myc trans-
locations. To determine whether Parp1 activity can modulate 
the Parp2-dependent suppression, we cultured Parp2/ B cells 
in the presence of the inhibitor. Under these conditions, the 
translocation frequency (5.6 × 107 translocations/cell; Fig. 5 F) 
was 3.7-fold higher than in wild-type B cells (P = 0.0139), 
similar to wild-type + KU0058948 (P = 0.5472) or Parp1/ 
+ KU0058948 (P = 0.4837), but reduced when compared 
with Parp2/ B cells (P = 0.0006). Thus, increased Parp1 
activity in Parp2/ B cells correlates with increased translo-
cation frequency and suggests that Parp1 modulates the sup-
pressor function of Parp2 by favoring repair through alternative 
NHEJ. To determine whether the increase in translocation 
frequency triggered by Parp inhibition is dependent on AID 
expression, we cultured AIDcre/cre B cells in the presence or   
absence of KU0058948. Consistent with previous reports   
(15–19), IgH/c-myc translocations were not observed in AID- 
deficient B cells (0 translocations/cell; Fig. 5 G). Furthermore, 
the increase in translocation frequency triggered by the inhibi-
tion of Parp activity was AID dependent (Fig. 5 H), as we did 
not detect any translocations in AIDcre/cre B cells that were cul-
tured in the presence of KU0058948 (0 translocations/cell; P = 
0.0005 vs. wild type + KU0058948; P = 0.0008 vs. Parp1/ + 
KU0058948; P = 0.0003 vs. Parp2/ + KU0058948). We 
conclude that the translocation suppressor function of Parp2 is 
AID dependent. Translocation sequence analysis revealed no 
significant differences between groups in either breakpoint dis-
tribution (in S and in c-myc) or in the amount of donor/ 
acceptor homology at the junction (Figs. S4 and S5). We con-
clude that Parp1 and Parp2 have nonredundant activities and 
that although Parp1 has no protective role, Parp2 suppresses 
AID-mediated IgH/c-myc translocations during CSR.
DISCUSSION
We have found that Parp activity is induced in an AID-depen-
dent manner in B cells undergoing CSR, and therefore induced 
in response to DNA breaks triggered by AID. Despite the induc-
tion of Parp activity, we found that disruption of Parp1 or Parp2, 
or the pharmacological inhibition of their catalytic activities, had 
no significant impact on the efficiency of the CSR reaction in 
cultured splenic B cells. Surprisingly, this is in contrast to the in-
creased CSR detected in the transformed cell lines CH12 (this 
study) and 1.29 (34) treated with a Parp inhibitor. Although we 
are unable to provide a molecular explanation for this observa-
tion, we speculate that the differential effect of Parp inhibition 
observed in primary B cells compared with CH12 cells might be 
related to the transformed state of the cell line, to unsuspected 
chromosomal aberrations (i.e., CH12 cells have three copies of 
the IgH locus; unpublished data), to differences in the frequency 
of AID-induced DNA breaks, or, alternatively, to the relative 
sequence homology between the S and S switch regions.
The intrinsic ability of splenic B cells to undergo CSR to 
all isotypes tested is not compromised in Parp1/ or Parp2/ 
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recruitment to DNA breaks is dependent on Parp1 and not 
Parp2 (48). Thus, it is possible that faster recruitment of Parp1 to 
DNA breaks followed by XRCC1 accumulation contributes to 
its specific role in facilitating alternative end-joining. In addition 
to a direct role in sensing DNA breaks, with the potential of be-
ing channeled into an interchromosomal translocation, it is pos-
sible that Parp2 exercises its suppressor function by enforcing the 
p53-dependent signal for oncogenic stress (17). This could be 
achieved by modulating the activity of the tumor suppressor 
p19Arf via the physical association of Parp2 with B23 (also known 
as nucleophosmin 1; reference 31), a nucleolar protein (49) that 
regulates the activity of p19Arf (50–55) and that has been previ-
ously implicated in CSR (56). In addition, it is possible that 
Parp2 suppresses IgH/c-myc translocations through p53-inde-
pendent pathways that would involve the posttranslational mod-
ification of effector proteins that have not yet been identified.
Our results establish that Parp1 and Parp2 respond to pro-
grammed DNA damage in B cells undergoing CSR, define a 
role for Parp1 in favoring DNA repair through the alternative 
NHEJ, and uncover Parp2 as a novel translocation suppressor 
during CSR.
MATERIALS AND METHODS
Mice. Parp1/ (24), Parp2/ (26), and AIDcre/cre (19) mice were bred and 
maintained under specific pathogen–free conditions. Age-matched littermates 
(8–12 wk old) obtained from heterozygous crosses were used in all experiments. 
All animal work was performed under protocols approved by the Direction des 
Services Vétérinaires du Bas-Rhin, France (authorization no. 67–343).
Lymphocyte cultures and flow cytometry. Resting B lymphocytes were 
isolated from the spleen using CD43 Microbeads (Miltenyi Biotec) labeled 
with 5 µM CFSE (Invitrogen) and cultured with 50 µg/ml LPS (Sigma- 
Aldrich), 5 ng/ml IL-4 (Sigma-Aldrich), or 100 ng/ml IFN- (Peprotech). 
CH12 cells were cultured with 5 ng/ml IL-4, 3 ng/ml hTGF- (R&D Sys-
tems), and 100 ng/ml monoclonal anti-CD40 antibody (eBioscience). The 
KU0058948 Parp inhibitor (AstraZeneca/KuDOS) (32) was diluted in PBS 
and used at a final concentration of 10 or 100 nM. To induce Parp activity, 
cells were treated for 10 min with 1 mM H2O2. For flow cytometry, cells were 
stained with biotin anti-IgG1 (BD), biotin anti-IgG3 (BD), biotin anti-IgG2b 
(BioLegend), biotin anti-IgG2a (BD), PE anti-IgA (SouthernBiotech), and 
PE-Streptavidin (Beckman Coulter). Dead cells were excluded from the analy-
sis by staining with 50 nM ToPro-3 (Invitrogen). Data were collected on a 
FACSCalibur (BD) and analyzed with the FlowJo software (Tree Star, Inc.).
Translocation PCR. PCR for detecting IgH/c-myc translocations was per-
formed using previously described primers and PCR conditions (15, 17). In 
brief, genomic DNA corresponding to 105 cells was submitted to 2 rounds of 25 
cycles of nested PCR using the Expand Long template PCR system (Roche). As 
positive control for amplification of all DNA samples, AID-specific primers (for-
ward,  5-GGACCCAACCCAGGAGGCAGATGT-3;  reverse,  5-CCTC-
TAAGGCTTCGCTGTTATTACCAC-3) were included in the first round 
of amplification. For PCR on AIDcre/cre genomic DNA, Cre specific primer   
(5-CACTCGTTGCATCGACCGGTAATG-3)  was  used  in  combination 
with AID forward primer. PCR products were analyzed by Southern blot using 
IgH and c-myc specific probes as previously described (15, 17). Genomic DNA 
obtained from at least three independent experiments and corresponding to 
20-30 × 106 cells was assayed for each genotype.
Switch junction analysis. S-S3 switch junctions were amplified using 
previously described primers (57) and conditions (14). PCR products were 
cloned using TOPO-TA cloning kit (Invitrogen) and sequenced using M13 
qualitative effect on the CSR reaction, as indicated by the na-
ture of the switch junction sequences. Switch junctions ob-
tained  from  Parp1-deficient  B  cells  displayed  a  clear  bias 
toward no homology, indicating that the alternative NHEJ 
was suppressed in the absence of Parp1, and that Parp1 favors 
the usage of a microhomology-based end-joining mechanism. 
This is consistent with the proposed role for Parp1 in compet-
ing with Ku80 for accessibility to DNA ends (40) and with the 
proposed role for Parp1, XRCC1, and DNA ligase III in me-
diating alternative end-joining (41–44). Our results support 
the hypothesis that Parp1 is part of the alternative NHEJ path-
way in mammalian cells and implicate the base excision repair 
proteins XRCC1 and DNA ligase III in the processing of 
AID-induced DNA breaks during CSR.
We have found that Parp1 and Parp2 have specific and 
nonredundant roles, and that although Parp1 has no protec-
tive role, Parp2 suppresses AID-mediated IgH/c-myc trans-
locations during CSR. The translocation suppressor function 
of Parp2 appeared, however, to be down-modulated by the 
addition of a Parp inhibitor, suggesting that the catalytic ac-
tivity of Parp1 may regulate the suppressor function of Parp2. 
Given the role of Parp1 in facilitating repair through a micro-
homology-based end-joining mechanism that frequently pro-
duces translocations (9) and the increased Parp1 activity that 
we observed in Parp2/ B cells (Fig. 1 B), it is possible that 
the translocation frequency observed in Parp2/ B cells re-
sults from the synergistic effect of a bias toward alternative 
NHEJ driven by increased Parp1 activity and by the lack of 
suppression by Parp2. Thus, inhibiting Parp activity in wild-
type, Parp1/, and Parp2/ B cells reveals the unique con-
tribution of Parp2 in suppressing IgH/c-myc translocations.
Despite the established shared functions of Parp1 and Parp2 
in the cellular response to DNA damage and in the maintenance 
of  heterochromatin  integrity,  recent  advances  reveal  unique 
functions that have only begun to be clarified (23). Parp1 and 
Parp2 have different substrates and targets both in DNA and in 
proteins (23), and they display substantial structural differences 
that could account for their differential requirement in facilitat-
ing alternative end-joining and in suppressing IgH/c-myc trans-
locations. For example, Parp1 and Parp2 differ in the structure 
of their DNA-binding domains (23, 25, 45), and as such may 
not recognize the same structures or be activated by the same 
type of DNA lesion. Indeed, it has been suggested previously 
that Parp2 displays higher affinity than Parp1 for gaps or flaps 
(25, 46), structures that we speculate may correspond to DNA 
ends that require substantial processing before joining and that 
may represent translocation intermediates. Parp1 and Parp2 also 
differ in their protein–protein interaction domains, and this may 
result in differential responses caused by specific partner recruit-
ment. In addition, Parp2 contains a 3-aa insertion in the vicinity 
of the catalytic pocket, which may contribute to fine tuning 
substrate selection and downstream effector specificity (47). No-
tably, Parp1 accumulates at sites of DNA damage with faster ki-
netics than Parp2 (48), suggesting that Parp1 may play a more 
prominent role in sensing DNA damage and that Parp2 may be 
required at later steps during DNA repair. Furthermore, XRCC1 JEM VOL. 206, May 11, 2009 
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